Streetbeat News

ARMP

Armata Pharmaceuticals, Inc.

https://www.armatapharma.com

Industry

Biotechnology

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Open

1.99

Mkt cap

76M

Volume

18K

High

2.16

P/E Ratio

-1.82

52-wk high

4.48

Low

1.99

Div yield

N/A

52-wk low

1.93

Armata Pharmaceuticals (AMEX:ARMP) reported Q4 earnings with a per-share loss of $(0.55), missing the $(0.35) estimate, marking a 57.14% miss and an 89.66% increase in losses from the previous year. However, their quarterly sales of $1.53M exceeded expectations by 77.67%, showing a 45.39% increase from the previous year.

Portfolio Pulse from Happy Mohamed

March 21, 2024 | 8:07 pm

Armata Pharmaceuticals has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of Innoviva, receiving $35 million in gross proceeds. This funding will be used to advance Armata's lead therapeutic phage candidates, AP‐PA02 and AP‐SA02, targeting Pseudomonas aeruginosa and Staphylococcus aureus infections.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:03 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Sana Biotechnology (SANA) led the gainers with a 45.2% increase, while DocGo (DCGO) saw the largest decline among the losers, dropping 35.2%. Other notable movers included Amarin Corp (AMRN), Vicarious Surgical (RBOT), and TG Therapeutics (TGTX). Market capitalizations were also highlighted, indicating the size of each company.

Portfolio Pulse from Benzinga Insights

January 10, 2024 | 5:31 pm

Armata Pharmaceuticals (AMEX:ARMP) reported a Q3 EPS loss of $(0.86), significantly missing the $(0.31) estimate, representing a 258.33% increase in losses year-over-year. However, sales of $1.23M exceeded expectations by 28.95%, despite being an 8.45% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:05 pm

Armata Pharmaceuticals has announced the presentation of topline data from its SWARM-P.a. clinical study of AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients at the North American Cystic Fibrosis Conference.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:08 pm

Armata Pharmaceuticals has initiated the Phase 2A portion of its diSArm study by dosing the first patient with AP-SA02, a treatment for Staphylococcus Aureus Bacteremia.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:13 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Armata Pharmaceuticals (AMEX:ARMP) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 3:10 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Femasys (FEMY), Mallinckrodt (MNK), Cutera (CUTR), Evolus (EOLS), INVO Bioscience (INVO), and Talkspace (TALK) saw their stocks rise, with Femasys leading the gainers with a 146.9% increase. On the other hand, Mersana Therapeutics (MRSN), Asensus Surgical (ASXC), Biohaven (BHVN), Bluejay Diagnostics (BJDX), Armata Pharmaceuticals (ARMP), and icad (ICAD) saw their stocks fall, with Mersana Therapeutics leading the losers with a 78.3% decrease.

Portfolio Pulse from Benzinga Insights

July 27, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most in Wednesday's mid-day session. Some of the top gainers include Silicon Motion Technology Corporation, Mallinckrodt plc, and ABVC BioPharma, Inc. due to various reasons such as merger approvals, potential bankruptcy plans, and new partnerships. On the other hand, some of the top losers include Dunxin Financial Holdings Limited, Carmell Therapeutics Corporation, and Inpixon due to reasons such as weak quarterly sales, pricing of registered direct offering, and merger agreements.

Portfolio Pulse from Lisa Levin

July 26, 2023 | 5:57 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Mallinckrodt (MNK), SCWorx (WORX), Armata Pharmaceuticals (ARMP), Teladoc Health (TDOC), Vincerx Pharma (VINC), and Aceragen (ACGN) saw their stocks rise, with Mallinckrodt leading the gainers with a 60.7% increase. On the other hand, Sage Therapeutics (SAGE), 180 Life Sciences (ATNF), Athersys (ATHX), Etao International Co (ETAO), Inozyme Pharma (INZY), and PaxMedica (PXMD) saw their stocks fall, with Sage Therapeutics leading the losers with a 13.8% decrease.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.